Disclosed is a composition of 10 wt % to 99 wt % of carbon dioxide absorbent or adsorbent, wherein the carbon dioxide absorbent or adsorbent is selected from the group consisting of inorganic hydroxides of alkali hydroxides and/or alkaline earth metal hydroxides, molecular sieves, zeolites, zinc (ii) ions, deep eutectic solvents and/or silica, whereby the composition contains 1 wt % to 90 wt %, relative to the total composition, of a polymeric coating selected from the group consisting of silicone rubber obtained from liquid silicone rubber and cellulose derivative for use in medicine for the prophylaxis and treatment of respiratory diseases in a mammal.

Disclosed is a process for the preparation of powder compositions including a lipophilic extract of Echinacea spp., a lipophilic extract of Zingiber officinale and phospholipids. Also disclosed are powder compositions obtainable by the process and pharmaceutical, nutraceutical and cosmetic formulations including the compositions. Also described is a use of the powder compositions and formulations thereof in the prevention and/or treatment of inflammatory and painful states.

The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino }-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

The invention refers to a pharmaceutical or nutraceutical composition comprising a core a) comprising an active ingredient and a water-insoluble polymer, a coating layer b) above the core a) comprising a salt of an alginic acid, and a coating layer c) above the coating layer b) comprising an anionic (meth)acrylate copolymer polymerized from a (meth)acrylate monomer mixture comprising 5-75% by weight in relation to the total weigh of the (meth)acrylate monomer mixture of (meth)acrylate monomers with an anionic group, wherein the amount of the water-insoluble polymer in the core a) is 2 to 20% by weight in relation to the weight of the corm a) and the amount of the salt of an alginic acid in the coating layer b) is 5 to 85% by weight in relation to the weight of the core a) and the amount of the anionic (meth)acrylate copolymer in the coaling layer c) is 10 to 75% by weight in relation to the weight of the care a) and to the coating layer b).

The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.

Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.